摘要
目的探讨以氨氯地平为基础的联合治疗方案,对高血压患者血压达标及血管事件的影响。方法为多中心随机开放对照盲终点评估的研究。50～79岁伴心血管病危险因素的高血压患者知情同意后,随机分为氨氯地平+复方阿米洛利组(A组,n=5805)或氨氯地平+替米沙坦组(B组,n=5805),主要终点是心血管病复合事件,治疗随访4年。结果2007年10月至2008年10月间180家合作单位共随机13134例患者,其中11610例数据初步分析:基线平均血压水平157/93mmHg,随机治疗后第8周A组与B组血压分别降至133.0/80.9mm Hg和132.9/80.3mm Hg。治疗第8周A组血压控制率达71.5%;B组血压控制率达72.0%。结论以氨氯地平为基础的联合降压治疗达到了良好的血压控制。
Objective To investigate the effect of a combined therapeutic scheme based on amlodipine and its influence on the blood pressure criteria and vascular events in hypertensive patients. Methods A multi-centre, randomized, open, controlled and blinded-endpoint study was carried out. On the basis of informed consent, the hypertensive patients aged from 50 to 79 with at least one cardiovascular risk factor, were randomly divided into the group of amlodipine combined with amiloride compound （ group A, n = 5805 ） and the group of amlodipine combined with telmisartan （ group B, n = 5805 ）. The primary endpoint under the investigation was cardiovascular compound event, which was treated and followed up for four years. Results There were 13 134 cases followed up from Oct. 2007 to Oct. 2008 in 180 cooperative units, among which the data of ll 610 cases were analyzed initially. The result showed that the average baseline blood pressure was 157/93 mm Hg （1 mm Hg =0. 133 kPa）. On 8th week after the random treatment, the blood pressure decreased to 133.0/80.9 mm Hg in group A and 132.9/80.3 mm Hg in group B. The rate of blood pressure control was 71.5% in group A and 72.0% in group B on 8th week. Conclusion The combined blood pressure lowering therapy based on amlodipine has a good effect on controlling blood pressure.
出处
《中国循证心血管医学杂志》
2008年第1期24-27,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
基金
国家十一五科技支撑计划课题(2006BAI01A03)
关键词
高血压
临床试验
治疗结果
Hypertension
Clinical trial
Treatment outcome
作者简介
共同第一作者：王文 张宇清
共同第一作者：王文 张宇清
通信作者：马丽媛，Email：maliyuan600@vip．sina．com
